Glycogen storage disease type II screening

Jump to navigation Jump to search

Glycogen storage disease type II Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glycogen storage disease type II from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glycogen storage disease type II screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glycogen storage disease type II screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glycogen storage disease type II screening

CDC on Glycogen storage disease type II screening

Glycogen storage disease type II screening in the news

Blogs on Glycogen storage disease type II screening

Directions to Hospitals Treating Glycogen storage disease type II

Risk calculators and risk factors for Glycogen storage disease type II screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Overview

According to the Recommended Uniform Screening Panel for newborn screening, screening for glycogen storage disease type 2 by Liquid Chromatography-Tandem Mass Spectrometry assay of leukocyte acid α-glucosidase is recommended for newborn.

Screening

  • Glycogen storage disease type 2 (GSD type 2) is the first lysosomal storage disease to be added to Recommended Uniform Screening Panel for newborn screening panel.[1][2][3]
  • Newborn screening for GSD type 2 by Liquid Chromatography-Tandem Mass Spectrometry assay of leukocyte acid α-glucosidase (GAA) is recommended.
  • Low residual GAA activity in leukocytes is determined by this assay.
  • Measurement of GAA in blood samples can partially differentiate between infantile onset GSD type 2, late-onset GSD type 2, and pseudodeficiency.

References

  1. Lin N, Huang J, Violante S, Orsini JJ, Caggana M, Hughes EE; et al. (2017). "Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease". Clin Chem. 63 (4): 842–851. doi:10.1373/clinchem.2016.259036. PMC 5413112. PMID 28196920.
  2. Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC; et al. (2008). "Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program". Pediatrics. 122 (1): e39–45. doi:10.1542/peds.2007-2222. PMID 18519449.
  3. Mechtler TP, Stary S, Metz TF, De Jesús VR, Greber-Platzer S, Pollak A; et al. (2012). "Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria". Lancet. 379 (9813): 335–41. doi:10.1016/S0140-6736(11)61266-X. PMID 22133539.


Template:WS Template:WH